Case studies
Our success is defined by our culture and shared ambition to create a positive impact, here you can find our caser studies which really showcase the best of our Commitment and our Purpose.
Coltide Radiance sustainability in use
In October we were delighted that our sustainability leadership was recognised as we won Business of the Year at the World Sustainability Awards.
CroBioticTM 100
Surveys indicate that malodour of garments is one of the biggest reasons that consumers choose to wash them.
Croda Foundation
We have taken a big step towards achieving our ambition of expanding the reach of our smart science to permanently improve more lives by funding the Croda Foundation.
Customer award for carbon reduction
We’ve been working in partnership with Syngenta to deliver innovative and sustainable ingredients in a way that meets their commercial and sustainability goals.
Customer driven
We are listening more closely to our customers than ever before; understanding the things that are of most importance to our customers and how we are performing against them.
Digitalisation in manufacturing
We can see the potential of big data, robotics, analytics and the Internet of Things to drive manufacturing excellence and contribute to our right first time agenda.
Diversity and inclusion
In 2021 we defined a D&I roadmap identifying actions, regarding diversity and inclusion, in five key areas.
Driving innovation in the Agriculture market
Through Croda’s acquisition of the Incotec Seed Enhancement business in 2015 and the Plant Impact Biostimulants business in 2018, we are well placed to address some of the challenges in the adoption...
Externally validated avoided emissions
The emissions savings of this new product were revealed during its sustainability assessment, part of the new way of working for our innovation teams to support our Commitment.
Focusing on D&I in Asia
Colleagues in Asia have been leading a programme of raising awareness, building an inclusive culture, and driving inclusivity in recruitment.
Human Performance programme
Our behavioural safety improvement programmes were standardised into a Group-wide Behavioural Safety Observation programme, implemented across all manufacturing sites since 2015.
Improving the customer experience in China
Our .CN website transformation, which was launched in 2020, has created an entirely new online experience for customers in fast-growing Chinese markets.
Investing in mRNA and gene therapy
As the core of our lipid systems capability within the Health Care business, Avanti is primarily focused on developing innovative lipid-based products of unparalleled purity to address specific...
Investing in organic expansion in Agriculture
Atlox 4913TM is valued by customers for creating stable dispersions in complex crop formulations, ensuring consistent distribution of actives and preventing formulation breakdown.
Leveraging expertise in UV filters for Asian markets
There are over three million cases of skin cancer globally each year, responsible for tens of thousands of deaths. Our range of sunscreens meets a clear need and is an important pillar of our...
Leveraging Group-wide capabilities to accelerate the development of natural active ingredients
The move in cosmetics towards replacing synthetic ingredients with sustainable alternatives is increasing demand for naturally sourced actives.
Net zero roadmap for UK manufacturing site
We became one of the first UK manufacturing sites to develop a 2050 net zero roadmap as part of the UK Government’s Department for Business, Energy and Industrial Strategy ‘Industry of the Future’...
New frontiers in fragrance and flavours
Croda acquired international fragrances and flavours company Iberchem in 2020, the largest acquisition in our history and a major move into a market strongly aligned with our business.
Croda supports Pfizer-BioNTech COVID-19 vaccine
Avanti, a company we acquired in 2020, has a strong track record in supplying R&D quantities of lipid-based drug delivery technologies to pharmaceutical companies including those developing mRNA drugs...